# A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

> **NCT00283634** · PHASE2 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.**

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** erlotinib and bortezomib

## Key facts

- **NCT ID:** NCT00283634
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2007-07
- **Final completion:** 2007-08
- **Target enrollment:** — (—)
- **Why stopped:** insufficient efficacy
- **Last updated:** 2011-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283634, "A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00283634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*